Breaking News

Strata Oncology Unveils Strata PATH Trial

The new platform clinical trial will evaluate FDA-approved therapies in novel biomarker profiles learned from real-world data.

Author Image

By: Charlie Sternberg

Associate Editor

Strata Oncology Inc., a precision oncology company advancing molecular indications for cancer therapies, has announced the Strata Precision Indications for Approved Therapies, or “Strata PATH,” trial.   Strata PATH is a multi-drug, multi-arm, biomarker-driven clinical trial designed to evaluate the efficacy of FDA-approved targeted- and immunotherapies in new Strata-defined biomarker indications. Pfizer Inc. will provide marketed, targeted drugs for four study arms at no cost to part...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters